Herbert Meltzer, M.D.
Bixler/May/Johnson Professor of Psychiatry and Professor of Pharmacology
Herbert.Meltzer@Vanderbilt.edu
Dr. Herbert Meltzer has been a member of the faculty since 1996. He is the Bixler/May/Johnson Professor of Psychiatry and Professor of Pharmacology at the Vanderbilt University School of Medicine where he is director of the Psychosis Program. He has received the Lieber Prize for Schizophrenia Research, Efron Award of the American College of Neuropsychopharmacology, the Gold Medal of the Society of Biological Psychiatry, and numerous other awards for his research in schizophrenia and its treatment. Dr. Meltzer has been the president of the American (ACNP) and the International (CINP) Colleges of Neuropsychopharmacology.
Education
B.A. Cornell University, Ithaca, New York
M.A. Harvard University, Cambridge, Massachusetts
M.D. Yale University, New Haven, Connecticut
Postgraduate Training
Intern in Medicine, St. Luke's Hospital, New York, New York
Resident in Psychiatry, Massachusetts Mental Health Center, Boston, Massachusetts
Areas of Clinical Expertise
Schizophrenia, psychopharmacology, antipsychotic drug development, cognition
Research interests
Investigating the cognitive deficit in schizophrenia; identification of new antipsychotic drugs; studying the mechanism of action of antipsychotic drugs; genes conveying risk for schizophrenia; pharmacogenetics; pharmacoeconomics; suicide prevention
Representative publications
1) Meltzer H, Alphs L, Green A. Altamura A, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam M, Kane J, Krishnan R, Lindenmayer J-P, Potkin S (2003): International Suicide Prevention Trial (InterSePT): reduced suicidality in schizophrenia with clozapine treatment. Archives of General Psychiatry 60(7):735.
2) Meltzer HY, Arvanitis L, Bauer D, Rein W (2004): A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry 161:6 2004
3) Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005). ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl);183(2):144-53, 2005.
4) Basu A, HY Meltzer (2006). Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophrenia Research 86(1-3):99-109, 2006
5) Woodward Neil D., Purdon E. Scot, Meltzer Herbert Y, Zald David H (2007). A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophrenia Research 89: 211-224.
